Trial Profile
An Open-Label Phase 2 Study of WGI-0301 Plus Sorafenib in Patients With Advanced Hepatocellular Carcinoma as Second Line Therapy
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs RX 0301 (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Proof of concept; Therapeutic Use
- Sponsors Zhejiang Haichang Biotechnology
- 14 Feb 2018 New trial record
- 08 Feb 2018 According to a Rexahn Pharmaceuticals media release, Zhejiang Haichang Biotechnology will fund this trial.